KRAS mutations are usually associated with the female sex, adenocarcinoma [7,24,27,29,30], and smoking [30]; therefore, patients with these clinical features are overrepresented compared to the average NSCLC stage III population [4,10,11]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.